Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2

1 day ago 1

Healthcare

Triple-negative breast cancer (TNBC) - closeup view 3d illustration

Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and Drug Administration (FDA) in H2 2025 targeting the U.S. approval of their jointly developed breast cancer therapy, vepdegestrant.

The decision comes

Recommended For You

More Trending News

Read Entire Article

Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2

Recommended For You

More Trending News

Related

Pre Market Setup (June 2): GIFT Nifty up 40 pts; markets lik...

Dow futures dip as Wall Street weighs likelihood of Trump’s ...

ZeniMax video game workers reach first union contract with M...

Credo Technology Q4 2025 Earnings Preview

Big Tech is back in S&P 500 driver’s seat as profit engines ...

Treasury Secy Bessent: China holding back products essential...

Bessent says Trump-Xi call would ease trade logjam — ‘I beli...

Exercise, including regular walks, boosts colon cancer survi...

Citi names Bank of America veteran Zhang as new China countr...

Fujitsu Technology Park's redevelopment project launch

Japan to raise foreign direct investment target to $1 trilli...

‘Lilo & Stitch’ tops box office again as summer movie season...

China robotaxis, Indian pharma among hedge fund top picks at...

Australia's BlueScope surges on Trump's plan to double tarif...

The tide is turning in the housing market as top metro areas...

Oil rallies as Russia-Ukraine tensions offset OPEC+ output h...

Trump administration targets contracts with tech firms for m...

Asia's factory activity shrinks in May as US tariffs bite

Australian job ads fall for second month in May, ANZ-Indeed ...

ASX-listed James Hardie secures $3.5 billion credit to fund ...

Trending

Popular

صعود نماینده ناین‌بال ایران به جمع ۸ بازیکن برتر جهان و کسب ...

تصمیم مهم درباره سهمیه بازیکنان خارجی